Financial incentives versus standard of care to improve patient compliance with live kidney donor follow-up: protocol for a multi-center, parallel-group randomized controlled trial
AuthorLevan, Macey L
Waldram, Madeleine M
DiBrito, Sandra R
Thomas, Alvin G
Al Ammary, Fawaz
Brennan, Daniel C
Massie, Allan B
Barth, Rolf N
Segev, Dorry L
Garonzik-Wang, Jacqueline M
MetadataShow full item record
AbstractBackground: Live kidney donors (LKDs) account for nearly a third of kidney transplants in the United States. While donor nephrectomy poses minimal post-surgical risk, LKDs face an elevated adjusted risk of developing chronic diseases such as hypertension, diabetes, and end-stage renal disease. Routine screening presents an opportunity for the early detection and management of chronic conditions. Transplant hospital reporting requirements mandate the submission of laboratory and clinical data at 6-months, 1-year, and 2-years after kidney donation, but less than 50% of hospitals are able to comply. Strategies to increase patient engagement in follow-up efforts while minimizing administrative burden are needed. We seek to evaluate the effectiveness of using small financial incentives to promote patient compliance with LKD follow-up. Methods/design: We are conducting a two-arm randomized controlled trial (RCT) of patients who undergo live donor nephrectomy at The Johns Hopkins Hospital Comprehensive Transplant Center (MDJH) and the University of Maryland Medical Center Transplant Center (MDUM). Eligible donors will be recruited in-person at their first post-surgical clinic visit or over the phone. We will use block randomization to assign LKDs to the intervention ($25 gift card at each follow-up visit) or control arm (current standard of care). Follow-up compliance will be tracked over time. The primary outcome will be complete (all components addressed) and timely (60 days before or after expected visit date), submission of LKD follow-up data at required 6-month, 1-year, and 2-year time points. The secondary outcome will be transplant hospital-level compliance with federal reporting requirements at each visit. Rates will be compared between the two arms following the intention-to-treat principle. Discussion: Small financial incentivization might increase patient compliance in the context of LKD follow-up, without placing undue administrative burden on transplant providers. The findings of this RCT will inform potential center- and national-level initiatives to provide all LKDs with small financial incentives to promote engagement with post-donation monitoring efforts. Trial registration: ClinicalTrials.gov number: NCT03090646 Date of registration: March 2, 2017 Sponsors: Johns Hopkins University, University of Maryland Medical Center Funding: The Living Legacy Foundation of Maryland © 2020, The Author(s).
Patient care management
Quality improvement, health care
Randomized control trial
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14104
- The Impact of the mKidney mHealth System on Live Donor Follow-Up Compliance: Protocol for a Randomized Controlled Trial.
- Authors: Henderson ML, Thomas AG, Eno AK, Waldram MM, Bannon J, Massie AB, Levan MA, Segev DL, Bingaman AW
- Issue date: 2019 Jan 15
- Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
- Authors: Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J
- Issue date: 2020 Oct 28
- Evidence Brief: Comparative Effectiveness of Appointment Recall Reminder Procedures for Follow-up Appointments
- Authors: Peterson K, McCleery E, Anderson J, Waldrip K, Helfand M
- Issue date: 2011
- The landscape of international living kidney donation in the United States.
- Authors: Al Ammary F, Thomas AG, Massie AB, Muzaale AD, Shaffer AA, Koons B, Qadi MA, Crews DC, Garonzik-Wang J, Fang H, Brennan DC, Lentine KL, Segev DL, Henderson ML
- Issue date: 2019 Jul
- A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
- Authors: Janssen M, Schäkel U, Djuka Fokou C, Krisam J, Stermann J, Kriegsmann K, Haberbosch I, Novotny JP, Weber S, Vehreschild M, Bornhäuser M, Bullinger L, Schmitt M, Liebregts T, Dreger P, Lorenz HM, Plaszczyca A, Bartenschlager R, Müller B, Kräusslich HG, Halama N, Jäger D, Schlenk RF, Leo A, Meuer S, Weigand MA, Motsch J, Merle U, Denkinger CM, Müller-Tidow C
- Issue date: 2020 Oct 6